06:38pm Sunday 16 February 2020

Weight loss reduces artery stiffness in Type 2 diabetes

Cardiovascular disease is the commonest cause of death in people with diabetes – accounting for 68% of all deaths.

Associate Professor Katherine Samaras from Sydney’s Garvan Institute of Medical Research and Associate Professor Christopher Hayward from St. Vincent’s Hospital have shown that arterial stiffness is directly associated with inflammation –  that is, activation of white blood cells and genes that regulate inflammation. Their findings are published in Diabetes and Vascular Disease Research, now online.

The study was based on 14 obese people with Type 2 diabetes or pre-diabetes. All participants underwent a calorie-restricted diet for 24 weeks, with gastric banding surgery after 12 weeks.

“We found that the degree of inflammation in fat tissue specifically predicted how much arteries relaxed during a weight loss program, meaning that people with higher levels of inflammation had arteries that did not relax as much,” said Associate Professor Samaras.

“Obesity, Type 2 diabetes and atherosclerosis are all associated with an inflammatory state, involving activation of immune cells in the circulation and in fat tissue, as well as an increase of circulating pro-inflammatory molecules.”

“Weight loss reduces immune cell activation and inflammation, which in turn is related to the extent that arteries can relax.”

“To our knowledge, this is the first study to examine the relationships between weight loss-induced improvements in arterial stiffness and the immune response.”

“We believe it supports clinical weight loss interventions, such as bariatric surgery, which enable people to lose weight for the long term and improve their health.”

The Garvan Institute of Medical Research was founded in 1963. Initially a research department of St Vincent’s Hospital in Sydney, it is now one of Australia’s largest medical research institutions with over 500 scientists, students and support staff. Garvan’s main research programs are: Cancer, Diabetes & Obesity, Immunology and Inflammation and Neuroscience. Garvan’s mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health. The outcome of Garvan’s discoveries is the development of better methods of diagnosis, treatment, and ultimately, prevention of disease.


All media enquiries should be directed to:
Alison Heather
Science Communications Manager

M: + 61 434 071 326
P: +61 2 9295 8128
E: a.heather “a” garvan.org.au




David Faktor,
Manager Public Affairs & Communications
St Vincents & Mater Health
+61 2 8382 2866
+61 405 497 510

Share on:

Health news